Does Anthem Cover Saxenda?

How Anthem Structures Prescription Drug Coverage for Weight-Loss Medications

Anthem plans divide drug benefits into tiers, and where Saxenda lands on that tier structure determines your out-of-pocket cost. Most Anthem commercial formularies place Saxenda on Tier 3 or Tier 4 (non-preferred or specialty), which means coinsurance rather than a flat copay. That distinction matters because Saxenda's list price is high enough that even a 20% coinsurance share can exceed $250 per month.

Anthem operates as a licensee of the Blue Cross Blue Shield Association across 14 states, and each state affiliate publishes its own formulary. The California affiliate (Anthem Blue Cross of California) may list Saxenda differently than the Ohio affiliate (Community Insurance Company, also branded Anthem). Checking the specific formulary for your plan year on the Anthem member portal, or calling the number on the back of your insurance card, is the only way to confirm your tier placement.

Employer self-funded plans add another layer of complexity. Under the Employee Retirement Income Security Act (ERISA), self-insured employers can exclude entire drug classes from coverage. A growing number of large employers have removed GLP-1 receptor agonists from their formularies entirely due to cost, even when those same drugs appear on Anthem's standard fully-insured formulary. The FDA's prescribing information for Saxenda notes the drug is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management [1].

A 2023 analysis published in JAMA Network Open found that only 27.3% of commercially insured adults with obesity had any pharmacy benefit coverage for anti-obesity medications, highlighting how inconsistent coverage remains across U.S. health plans [2].

What Prior Authorization Criteria Does Anthem Typically Require?

Prior authorization (PA) is nearly universal for Saxenda on Anthem plans, and the criteria follow a consistent pattern across most state affiliates.

BMI thresholds. Anthem's standard medical necessity criteria generally require a BMI of 30 or above, or a BMI of 27 or above accompanied by at least one weight-related comorbidity. Qualifying comorbidities typically include type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. These thresholds mirror the FDA-approved indication for Saxenda [1].

Documented diet and exercise program. Most Anthem PA requests require evidence that the patient has participated in a medically supervised or structured behavioral weight-loss program for at least three to six months before starting a prescription weight-loss agent. Clinician notes documenting counseling sessions, dietary logs, or enrollment in a formal program such as the National Diabetes Prevention Program satisfy this requirement in most cases.

Step therapy requirements. A number of Anthem plan variants require step therapy, meaning the patient must try and fail (or have a documented contraindication to) a lower-cost weight-loss medication before Saxenda will be approved. Phentermine/topiramate ER (Qsymia) or orlistat are the most common first-step agents specified in Anthem utilization management guidelines. The American Association of Clinical Endocrinology (AACE) 2022 Obesity Guidelines state that anti-obesity pharmacotherapy should be individualized based on comorbidities, contraindications, and patient preference, a principle that can be invoked to challenge a step-therapy denial [3].

Ongoing authorization. PA approvals for Saxenda are typically granted for 12 months, with renewal contingent on demonstrating at least 5% body weight loss from baseline. If a patient does not reach this threshold, Anthem may decline renewal. The SCALE Obesity and Prediabetes trial (N=3,731) reported that 63.2% of patients on liraglutide 3 mg achieved at least 5% weight loss at 56 weeks, compared with 27.1% on placebo [4], which gives most patients a reasonable basis for renewal.

Does Anthem Medicaid Cover Saxenda?

Anthem administers Medicaid managed care programs in several states, including California (Medi-Cal), Virginia, Indiana, and Georgia. Medicaid formulary decisions are made at the state level and then administered by the managed care organization, so coverage for Saxenda varies considerably.

California's Medi-Cal program does not currently list Saxenda on the preferred drug list for most beneficiaries. Virginia's Medicaid program covers anti-obesity pharmacotherapy under certain conditions but has historically required PA with strict BMI and comorbidity documentation. Indiana and Georgia Medicaid plans administered by Anthem generally follow similar PA frameworks.

Because Medicaid drug coverage is subject to annual state budget cycles and rebate negotiations with Novo Nordisk, the coverage status for Saxenda can change mid-year. Patients on Anthem Medicaid should request a written benefit determination each plan year and keep a copy on file. The Centers for Medicare and Medicaid Services (CMS) provides updated guidance on covered outpatient drugs under Medicaid Section 1927 [5].

Does Anthem Medicare Advantage Cover Saxenda?

This is a common source of confusion. Traditional Medicare Part D did not cover prescription weight-loss drugs until the Treat and Reduce Obesity Act language was incorporated into the Inflation Reduction Act framework discussions. As of 2025, CMS finalized a rule allowing Medicare Part D plans to cover GLP-1 medications approved for obesity when those medications also carry a cardiovascular risk-reduction indication.

Saxenda does not yet carry an approved cardiovascular risk-reduction label in the same way semaglutide (Wegovy) does following the SELECT trial. That distinction matters for Medicare Part D coverage. Anthem Medicare Advantage plans therefore vary: some cover Saxenda under the medical benefit for obesity treatment counseling, while most do not cover it under the Part D pharmacy benefit for weight-loss purposes alone. Patients enrolled in Anthem Medicare Advantage plans should call the plan directly and ask specifically whether liraglutide 3 mg (Saxenda) appears on the Part D formulary or under any supplemental benefit.

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% vs. placebo in adults with overweight or obesity and established cardiovascular disease [6], and the resulting labeling update for Wegovy (not Saxenda) is what opened the Medicare Part D pathway.

How to Get Saxenda Covered by Anthem: Step-by-Step

Getting prior authorization approved requires organization. The following process reflects current Anthem PA workflows.

Step 1: Confirm your formulary status. Log into anthem.com, manage to "Find a Drug," and search for "liraglutide 3 mg" or "Saxenda." Note the tier and any listed PA requirements.

Step 2: Have your prescriber submit the PA request. Anthem PA forms for specialty drugs are typically submitted through CoverMyMeds or Anthem's provider portal. The prescriber needs to document: current BMI, weight-related comorbidities, prior behavioral weight-loss program participation, contraindications to lower-cost alternatives (if step therapy applies), and the clinical rationale.

Step 3: Gather supporting clinical notes. Lab results showing HbA1c, lipid panel, or blood pressure readings strengthen the PA by demonstrating metabolic need. Include office visit notes from the past three to six months.

Step 4: Request an expedited review if medically necessary. Anthem is required under state insurance law and ERISA regulations to complete standard PA reviews within 72 hours (non-urgent) and 24 hours (urgent). Expedited review requires clinical documentation of urgency.

Step 5: Appeal a denial. If the initial PA is denied, the prescriber receives a denial notice with the specific clinical criteria not met. A first-level internal appeal should directly address each unmet criterion with additional documentation. Under the Affordable Care Act, insurers must provide a written rationale for each denial. The American Heart Association notes that excess body weight carries significant cardiovascular risk, making the clinical case for treatment straightforward for most patients with comorbidities [7].

Step 6: Request an external independent review. If the internal appeal fails, state law in most Anthem-operating states entitles patients to an independent external review by a board-certified physician not affiliated with Anthem. External reviews overturn insurer decisions at rates ranging from 30 to 60 percent for specialty medications in published analyses.

What Does Saxenda Cost Without Anthem Coverage?

Without insurance, Saxenda's cash price at major retail pharmacies sits between $1,349 and $1,449 for a 30-day supply (five 3 mL prefilled pens, each delivering 18 mg of liraglutide). Novo Nordisk offers two assistance options for patients who do not have adequate coverage.

Novo Nordisk Saxenda Savings Card. Commercially insured patients (not Medicare or Medicaid) who qualify can pay as little as $25 per month for up to 24 months. The card is available at saxenda.com and requires completion of an enrollment form. Income and insurance eligibility criteria apply.

Novo Nordisk Patient Assistance Program (PAP). Uninsured or underinsured patients who meet income thresholds (generally at or below 400% of the federal poverty level) may qualify for free medication through the PAP. Applications are submitted through Novo Nordisk Patient Assistance at novonordisk-us.com.

GoodRx and similar discount programs may offer partial reductions, bringing the price to approximately $1,100 to $1 to 200 in some markets, though these programs cannot be combined with insurance benefits.

How Saxenda Compares to Other Covered GLP-1 Options Under Anthem

Anthem plans vary in how they cover the full GLP-1 class, and a prescriber's choice of agent can affect insurance reimbursement significantly.

Wegovy (semaglutide 2.4 mg). Anthem commercial plans cover Wegovy for chronic weight management with PA in most fully-insured plan types. Wegovy's SELECT cardiovascular outcomes data [6] and its FDA label for cardiovascular risk reduction in appropriate patients have made it more formulary-friendly than Saxenda in 2024 and 2025.

Ozempic (semaglutide 1 mg / 2 mg). FDA-approved for type 2 diabetes, not weight loss. Anthem covers Ozempic broadly for patients with a confirmed type 2 diabetes diagnosis. Off-label use for weight management alone is generally not covered and may trigger a pharmacy claim rejection.

Victoza (liraglutide 1.2 mg / 1.8 mg). Liraglutide at lower doses, approved for type 2 diabetes. Covered by Anthem under the diabetes tier for qualifying diagnoses. Saxenda and Victoza share the same active ingredient but different doses and indications; switching between them for coverage purposes is not clinically equivalent and should not be attempted without physician supervision.

Zepbound (tirzepatide 2.5 to 15 mg). FDA-approved for chronic weight management in 2023. Anthem commercial formulary placement for Zepbound is evolving, with some plans adding it as a preferred weight-loss agent over Saxenda given the weight-loss magnitude seen in SURMOUNT-1 (N=2,539), where tirzepatide 15 mg achieved 20.9% mean weight loss at 72 weeks vs. 3.1% placebo [8].

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has stated: "The choice of anti-obesity medication should be driven by efficacy, comorbidity profile, and patient tolerability, not by which drug happens to be on a lower formulary tier this year." That principle applies directly when navigating coverage decisions with insurers like Anthem.

Clinical Evidence Supporting Saxenda Coverage Requests

When writing a letter of medical necessity for a PA or appeal, anchoring the argument in published clinical trial data strengthens the case significantly.

The SCALE Obesity and Prediabetes trial enrolled 3,731 adults with a BMI of 30 or above (or 27 with dyslipidemia or hypertension). Participants on liraglutide 3 mg lost a mean 8.4 kg (8.0% of body weight) at 56 weeks vs. 2.8 kg (2.6%) on placebo. At that same time point, 63.2% of liraglutide participants vs. 27.1% of placebo participants achieved at least 5% weight loss [4]. These are the efficacy benchmarks Anthem's own PA criteria reference.

The SCALE Maintenance trial (N=422) showed that patients who had already lost at least 5% of body weight on a low-calorie diet and then received liraglutide 3 mg maintained an additional 6.2% weight loss over 56 weeks vs. a 0.2% loss with placebo [9]. This trial is particularly useful in PA renewal documentation.

Cardiovascular risk data matter too. Patients with obesity carry a substantially elevated risk of type 2 diabetes, hypertension, heart failure, and certain cancers. The CDC reports that adults with obesity are approximately five times more likely to develop type 2 diabetes than adults at a healthy weight [10]. Documenting these downstream risks in the PA letter frames weight treatment as preventive medicine, not cosmetic intervention.

What to Do If Anthem Denies Saxenda Coverage

A denial is not a final answer. The following options remain.

First-level internal appeal. Submit within 180 days of the denial notice (ACA requirement). Include a letter of medical necessity from the prescribing physician that directly addresses each criterion listed as unmet in the denial.

Second-level internal appeal. If the first fails, Anthem's process allows a second internal review, often conducted by a different medical reviewer.

External independent review. Available after internal appeals are exhausted or after 72 hours in urgent cases. The external reviewer is a board-certified physician paid by a neutral third party.

State insurance commissioner complaint. Filing a complaint triggers a state-level review of whether the denial complied with applicable insurance law, including any state-level mandates for obesity treatment coverage.

Alternative medication request. If the denial is based on step therapy, the prescriber can document a clinical contraindication to the required first-step drug (for example, cardiovascular history precluding phentermine use) and request a step-therapy exception.

The Endocrine Society's 2015 Pharmacological Management of Obesity guidelines state: "We recommend that clinicians use medications only as an adjunct to diet, exercise, and behavior modification," and explicitly endorse pharmacotherapy for patients meeting BMI criteria who have not achieved adequate weight loss with lifestyle modification alone [11]. Citing named guidelines in appeal letters shifts the burden to Anthem to explain why its coverage decision departs from specialty society guidance.